Lexicon Pharma (LXRX) Reports In-Line Q4 EPS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Lexicon Pharma (LXRX) Reports In-Line Q4 EPS

Lexicon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical Update

May 5, 2022 6:00 AM EDT

THE WOODLANDS, Texas, May 05, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended March 31, 2022 and provided an update on key milestones.

We plan to resubmit our New Drug Application (NDA) for sotagliflozin for the treatment of heart failure this month having received confirmation from the FDA in late April... More